title: New platinum(II) complexes conjugated at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: design, synthesis, structure-activity relationships and biological evaluation.
abstract: Prostate cancer is a major public health problem worldwide and, more specifically, new treatments for hormone-refractory cancers are highly sought by several research groups. Although platinum(II)-based chemotherapy and other strategies grow in interest to treat castration-resistant prostate cancer (CRPC), they still exhibit modest activity on CRPC and overall patient survival. In this study, we designed and prepared new combi-molecules using 17β-acetyl-testosterone and amino acid platinum(II) complexes linked at the position 7α to target and to improve the antiproliferative activity of platinum(II)-based chemotherapy on prostate cancer cells. Twelve chemical intermediates and six new combi-molecules were prepared and characterized. Structure-activity relationships studies show that the platinum complex moiety is essential for an optimal cytocidal activity. Moreover, stereochemistry of the amino acid involved in the platinum complexes had only minor effects on the antiproliferative activity whereas pyridinyl (10a and b) and thiazolyl (10f) complexes exhibited the highest cytocidal activities that are significantly superior to that of cisplatin used as control on human prostate adenocarcinoma LNCaP (AR+), PC3 (AR-) and DU145 (AR-). Compounds 10a, b and f arrested the cell cycle progression in S-phase and induced double strand breaks as confirmed by the phosphorylation of histone H2AX into γH2AX. Compounds 10a and f showed 33 and 30% inhibition, respectively of the growth of HT-1080 tumors grafted onto chick chorioallantoic membranes. Finally, compounds 10a and 10f exhibited low toxicity on the chick embryos (18 and 21% of death, respectively), indicating that these new combi-molecules might be a promising new class of anticancer agents for prostate cancer.
authors.affiliation: Département de Chimie et Physique et, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, Québec, Canada G9A 5H7; Département de Biologie Médicale, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, Québec, Canada G9A 5H7. Electronic address: Sebastien.Fortin1@uqtr.ca.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Fortin
authors.forename: Kevin
authors.initials: K
authors.lastname: Brasseur
authors.forename: Nathalie
authors.initials: N
authors.lastname: Morin
authors.forename: Éric
authors.initials: É
authors.lastname: Asselin
authors.forename: Gervais
authors.initials: G
authors.lastname: Bérubé
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D001681:Biological Assay; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002642:Chick Embryo; D015195:Drug Design; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D023421:Models, Animal; D009942:Organometallic Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D010984:Platinum / Q000737:chemistry*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity
chemical_list: C115972:17-O-acetyltestosterone; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013739:Testosterone; D010984:Platinum
keywords: 17β-Acetyl-testosterone; AR; Anticancer agents; CAM; CDDP; CRPC; Combi-molecules; PSA; Platinum(II) complexes; Prostate cancer; androgen receptor; castration-resistant prostate cancer; chick chorioallantoic membrane; cisplatin; prostate-specific antigen